share_log

Cantor Fitzgerald Reiterates Overweight on Corvus Pharma, Maintains $4 Price Target

Cantor Fitzgerald Reiterates Overweight on Corvus Pharma, Maintains $4 Price Target

坎托·菲茨杰拉德重申对Corvus Pharma的增持,维持4美元的目标股价
Benzinga ·  2023/09/07 10:42

Cantor Fitzgerald analyst Li Watsek reiterates Corvus Pharma (NASDAQ:CRVS) with a Overweight and maintains $4 price target.

Cantor Fitzgerald分析师Li·沃塞克重申增持Corvus Pharma(纳斯达克:CRVS),并维持4美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发